GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atea Pharmaceuticals Inc (NAS:AVIR) » Definitions » Other Current Assets

AVIR (Atea Pharmaceuticals) Other Current Assets : $7.63 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Atea Pharmaceuticals Other Current Assets?

Atea Pharmaceuticals's other current assets for the quarter that ended in Dec. 2024 was $7.63 Mil.

Atea Pharmaceuticals's quarterly other current assets declined from Jun. 2024 ($4.16 Mil) to Sep. 2024 ($4.09 Mil) but then increased from Sep. 2024 ($4.09 Mil) to Dec. 2024 ($7.63Mil).

Atea Pharmaceuticals's annual other current assets declined from Dec. 2022 ($14.21 Mil) to Dec. 2023 ($12.35 Mil) declined from Dec. 2023 ($12.35 Mil) to Dec. 2024 ($7.63 Mil).


Atea Pharmaceuticals Other Current Assets Historical Data

The historical data trend for Atea Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atea Pharmaceuticals Other Current Assets Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Assets
Get a 7-Day Free Trial 7.54 8.03 14.21 12.35 7.63

Atea Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.35 7.27 4.16 4.09 7.63

Atea Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Atea Pharmaceuticals Other Current Assets Related Terms

Thank you for viewing the detailed overview of Atea Pharmaceuticals's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Atea Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Executives
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Jean-pierre Sommadossi director, 10 percent owner, officer: President, CEO, and Chairman 125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Bruce Polsky director C/O VISION-SCIENCES, INC., 40 RAMLAND ROAD, ORANGEBURG NY 10962
Andrea Corcoran officer: See Remarks 125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Janet Mj Hammond officer: Chief Development Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
John Vavricka officer: Chief Commercial Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Maria Arantxa Horga officer: Acting Chief Medical Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Wayne Foster officer: See Remarks 125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Polly A. Murphy director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Jerome M. Adams director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp 10 percent owner 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund I, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Rock Springs Capital Llc 10 percent owner 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202